FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* DAWES KAREN A						2. Issuer Name and Ticker or Trading Symbol PDL BIOPHARMA, INC. [PDLI]								cable) or	g Pers	10% Ov	vner	
(Last)						Date of Earliest Transaction (Month/Day/Year)								(give title	C a	Other (s	specify	
C/O PDL BIOPHARMA, INC.						10/04/2007								airpersor	1 OI U	ie Board		
1400 SE	APORT BL	L																
(Street)						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)				
REDWOOD CA 940			94063									X Form filed by One Reporting Person				n		
													Form f Persor		re thar	one Repo	rting	
(City)	(Si	tate)	(Zip)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)					Execution Date			, Transaction Dispose Code (Instr. 5)		Disposed	ities Acquired (A) or d Of (D) (Instr. 3, 4 a		Benefici	es ally Following	Form ly (D) o		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	,	Amount	(A) oi (D)	Price	Transact (Instr. 3	tion(s)			(111501.4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	rivative Conversion Date Exec curity or Exercise (Month/Day/Year) if any			Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exer Expiration E (Month/Day)		7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Shares						
Stock Option (Right to Buy)	\$23.63	10/04/2007		A		25,000		(1)	10	0/04/2014	Common Stock	25,000	\$0	25,000	0	D		

Explanation of Responses:

1. This option will vest monthly with respect to 1/12 of the shares subject to the option begining November 4, 2007. Only vested options are exercisable.

Remarks:

/s/ Francis Sarena by Francis Sarena, Attorney-in-Fact for

10/05/2007

Karen A. Dawes

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.